Article
Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
Neuro-oncology - 6 Jul 2023
Aquilanti Elisa, Kageler Lauren, Watson Jacqueline, Baird Duncan M, Jones Rhiannon E, Hodges Marie, Szegletes Zsofia M, Doench John G, Strathdee Craig A, Figueroa Jose Ricardo Mc Faline, Ligon Keith L, Beck Matthew, Wen Patrick Y, Meyerson Matthew
Abstract excerpt
BACKGROUND: Glioblastoma is one of the most lethal forms of cancer, with 5-year survival rates of only 6%. Glioblastoma-targeted therapeutics have been challenging to develop due to significant inter- and intra-tumoral heterogeneity. Telomerase reverse transcriptase gene (TERT) promoter mutations are the most common known clonal oncogenic mutations in glioblastoma. Telomerase is therefore considered to be a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.